ArborGen Holdings Limited (NZX: ARB) has announced strong results for the twelve months ended 31 March 2022 (FY22), delivering its highest ever US advanced genetics sales year – 32% higher than the prior year.

Operating earnings (before other significant items) of US$2.7 million for continuing operations in US and Brazil, up from $1.0 million in FY21, and an adjusted US-GAAP EBITDA result of $10.1 million excluding the New Zealand and Australian operations sold and other significant items, up from $7.4 million in the prior year.

The Company also completed the sale of its New Zealand and Australian businesses, significantly strengthening its balance sheet.

These results demonstrate ArborGen’s commitment to building advanced genetics seed inventory to minimise reliance on single year cone harvests, and the successful execution of its advanced genetics strategy.

See more